UnitedHealth investors may seek roadmap on costs as Hemsley takes center stage
(Reuters) -UnitedHealth's newly returned CEO, Stephen Hemsley, will likely face investor scrutiny over the largest U.S. health insurance and services company's efforts to rein in the elevated medical costs behind the withdrawal of its annual forecast.
Hemsley returned to the role in May following the abrupt departure of then-CEO Andrew Witty, who stepped down amid rising operational and financial pressures.
The company's decision in May to withdraw its 2025 earnings forecast due to soaring medical costs and Medicare-related challenges sent its shares tumbling.
So far this year, UnitedHealth's stock has plunged more than 40%, dragging down the broader managed care sector with it.
"Investors will be looking for confidence that he (Hemsley) has got a handle on things and that he understands where things may have gone wrong and how they are going to correct it," said James Harlow, senior vice president at Novare Capital Management, which owns 46,333 shares of the healthcare company.
Hemsley, who ran the company from 2006 to 2017, has promised to rebuild trust, telling shareholders last month that regaining their confidence is a top priority.
The pressure is compounded by a federal investigation into UnitedHealth's Medicare billing practices. The company recently confirmed it was cooperating with both criminal and civil inquiries from the U.S. Department of Justice. These regulatory woes have only added to the uncertainty facing the insurer.
Wall Street analysts have lowered expectations throughout this month. Analysts expect a profit of $4.48 per share for the second quarter, according to data compiled by LSEG. That compares with expectations of $5.70 per share in May, when the company suspended its annual profit forecast.
UnitedHealth plans to establish "a prudent 2025 earnings outlook and offer initial perspectives for 2026," the company had said in June.
"Ultimately, on Tuesday, what we'd expect is more clarity on the way forward...we would expect a strategy, a roadmap laid out," said Sahil Bhatia, managing director of life sciences at Manning & Napier.
"I think one of the big issues over the last few months has been just the surprises...so we would expect more consistent execution going forward after laying out that roadmap," Bhatia said.
At least two investors said they anticipate UnitedHealth will reset its 2025 profit forecast in the range of $18 to $20 per share, far below the company's previous outlook of $26 to $26.50.
This might be conservative but is an appropriate start for Hemsley's first call, said Jeff Jonas, portfolio manager at Gabelli Funds.
UnitedHealth has previously built a reputation to guide conservatively and raise its outlook as the year progresses.
But this time, investors warn, withholding guidance altogether would be damaging. "If they continue to not give an EPS outlook for 2025, that will be damaging," Harlow added.
Apart from financial turbulence, the company has also faced reputational challenges. It has moved to ease prior authorization requirements after a public outcry following the killing of a UnitedHealth executive last December.
The Optum unit, once a growth driver for UnitedHealth, has also emerged as a key area of concern. Last quarter, the company flagged "unanticipated changes" in its Optum business that impacted planned 2025 reimbursements.
"Among all the overhangs, Optum Health remains the biggest concern," said Deutsche Bank analyst George Hill.
UnitedHealth has also grappled with the fallout from a major cyberattack last year that disrupted claims processing across its Change Healthcare unit.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Berkshire takes $3.8 billion Kraft Heinz write-down, operating profit falls
By Jonathan Stempel (Reuters) -Warren Buffett's Berkshire Hathaway said on Saturday it took a $3.76 billion write-down on its stake in Kraft Heinz during the second quarter, an acknowledgment the decade-old investment hasn't worked out. Berkshire also reported a 4% decline in quarterly operating profit as insurance underwriting premiums fell. The write-down and lower gains from common stocks caused a 59% drop in overall net income. Buffett's conglomerate signaled it remains cautious about market valuations, amid uncertainty about tariffs and growth in the broader economy. It reported a near-record $344.1 billion cash stake, and sold more stocks than it bought for an 11th straight quarter. As of mid-July, Berkshire hadn't repurchased any of its own stock since May 2024. Buffett, 94, has led Omaha, Nebraska-based Berkshire since 1965, though he plans to step down at year-end. "Investors are getting antsy and want to seek activity, and nothing is happening," said Kyle Sanders, an analyst at Edward Jones. "Buffett definitely views the market as overvalued, and will sit back and wait for something to come to him." Uncertainty about trade policies, including tariffs, has become a headwind as delayed orders and shipments led to declining revenue at most of Berkshire's consumer businesses. Jazwares, which makes the popular Squishmallows plush toys, saw revenue fall 38.5% in the year's first half. Analysts viewed overall results as lackluster. "Berkshire and the economy are at an inflection point," said Cathy Seifert, a CFRA Research analyst. "I don't think the market will embrace the combination of mediocre results, a lack of stock buybacks, and Berkshire's recent share underperformance amid a management transition." Seifert and Sanders rate Berkshire "hold." KRAFT HEINZ Second-quarter operating income fell to $11.16 billion, or about $7,760 per Class A share, from $11.6 billion a year earlier. Results included $877 million of currency losses as the U.S. dollar weakened. Net income, including gains and losses on stocks such as Apple and American Express, fell to $12.37 billion from $30.35 billion. Revenue fell 1% to $92.52 billion. Buffett views unrealized investment gains and losses, including on stocks Berkshire has no plans to sell, as often meaningless to understanding his company. The $3.76 billion after-tax write-down for Berkshire's 27.4% Kraft Heinz stake, equal to $5 billion before taxes, followed the struggling food company's announcement it would consider strategic alternatives, which could include a breakup. Berkshire had carried Kraft Heinz on its books at above-market value but said economic and other uncertainties, and its longer-term plans to remain an investor, made the gap "other-than-temporary." The write-down is Berkshire's second for Kraft Heinz, following a $3 billion write-down in 2019. Buffett acknowledged at the time that Berkshire overpaid in the 2015 merger of Kraft Foods and H.J. Heinz, one of his biggest investment missteps. Kraft Heinz has suffered as more shoppers favor healthier and private-label alternatives. Its approximately 200 brands include Oscar Mayer, Kool-Aid, Velveeta and Jell-O. Berkshire also carries another big investment, its 28.1% stake in Occidental Petroleum at $5.3 billion above fair value, but reported no need for a write-down. LAGGING THE MARKET Shares of Berkshire have fallen more than 12%, and lagged the Standard & Poor's 500 by about 22 percentage points, since Buffett announced on May 3 he would step down as chief executive at year end. Vice Chairman Greg Abel, 63, will succeed him, though Buffett will remain chairman. Analysts said the premium embedded in Berkshire's stock price because of the presence of Buffett, arguably the world's most well-known investor, has eroded, while growth may slow in the insurance sector, a major Berkshire profit center. The lack of new investments has also been a drag. Analysts believe Berkshire's BNSF unit could buy CSX to create another transcontinental railroad, after Union Pacific agreed on July 29 to buy Norfolk Southern. Buffett transformed Berkshire over six decades from a troubled and since-closed textile company into a $1.02 trillion conglomerate. Berkshire owns several insurers and reinsurers, electric utility and renewable energy businesses, several chemical and industrial companies, and familiar consumer brands such as Dairy Queen, Fruit of the Loom and See's Candies. BIG BEAUTIFUL BILL Berkshire said the 12% quarterly decline in insurance underwriting profit stemmed primarily from reinsurance businesses and some smaller insurance businesses. Geico, its best-known insurance business, saw pre-tax underwriting profit rise 2%, as a 5% increase in premiums offset a smaller rise in accident losses. The car insurer has been ceding market share to State Farm and Progressive, while focusing on improving underwriting quality and technology and cutting jobs. Analysts said higher tariffs could be a headwind for Geico if the cost of auto parts rose, potentially increasing losses from accident claims. BNSF is also cutting expenses. Lower fuel costs helped boost quarterly profit 19% gain, though revenue and cargo volumes barely changed. The energy business, Berkshire Hathaway Energy, posted a 7% profit increase. Berkshire said it is evaluating the impact of the One Big Beautiful Bill Act, signed last month by U.S. President Donald Trump, on the "economics and viability" of its renewable energy, storage and technology-neutral projects.
Business Upturn
3 hours ago
- Business Upturn
UNITEDHEALTH CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against UnitedHealth Group Incorporated and Encourages Investors to Contact the Firm
NEW YORK, Aug. 02, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against UnitedHealth Group Incorporated ('UnitedHealth' or the 'Company') (NYSE: UNH) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired UnitedHealth securities between December 3, 2024 and April 16, 2025, both dates inclusive (the 'Class Period'). Investors have until July 7, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) UnitedHealth had, for years, engaged in a corporate strategy of denying health coverage in order to boost its profits, and ultimately, its share price; (2) this anti-consumer (and at times unlawful) strategy resulted in regulatory scrutiny (as well as public angst) against UnitedHealth, which ultimately resulted in the murder of Brian Thompson ('Thompson'); (3) animus towards UnitedHealth was such that, subsequent to the murder of Thompson, many Americans openly celebrated his demise, expressed admiration for his accused killer, and/or otherwise demanded that UnitedHealth change its strategy even if they condemned Thompson's killing; (4) the foregoing regulatory and public outrage caused UnitedHealth to change its corporate practices; (5) notwithstanding the foregoing, UnitedHealth recklessly stuck with the guidance it issued the day before Thompson's murder, which was unrealistic considering UnitedHealth's changing corporate strategies; and (6) as a result, defendants' public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. If you purchased or otherwise acquired UnitedHealth shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit . Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, Walker, Passmore, Esq.(212) 355-4648 [email protected]
Yahoo
7 hours ago
- Yahoo
What Lies Ahead for Long-Term Investments in Grains?
The US dollar index moved into a long-term uptrend at the end of July indicating the US Federal Open Market Committee could raise interest rates over the coming months. Fundamentally, the corn market looks to have the most fundamental reason to rally over the next year. More News from Barchart With UnitedHealth Under DOJ Investigation, Should You Buy, Sell, or Hold UNH Stock Now? Trump Won't Take Away Tesla's Subsidies. Does That Make TSLA Stock a Safe Buy Here? Can AMD Stock Hit $210 in 2025? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Soybeans and wheat could continue to drift until reads on real fundamentals grow more bullish. As I talked about last time, the US dollar index moved into an uptrend on its long-term monthly chart at the end of July. The implications of this, from a fundamental point of view, is that the US Federal Open Market Committee could raise the Fed fund rate over the coming months rather than making the cuts demand by the US president. Why? Based on my Market Rule #5, I don't like to spend as much time as most others in the industry making up reasons for something, but in this case the picture is clear: Interest rates would go up to strengthen the dollar to fight the inflation that is all but inevitable when trade wars and tariffs are used as the primary form of 'policy' (I use that term loosely to describe the current situation). Where did all this leave a handful of key investment markets at the end of July, from a technical point of view? Let's take a look. The US dollar index ($DXY) did complete a bullish key reversal[i] during July, confirming a move to a long-term uptrend. Given the main fundamental factor of the dollar is interest rates, the implication is the US Federal Open Market Committee could raise rates over the coming months rather than make cuts. We'll see. It should be noted monthly stochastics moved back ABOVE the oversold level of 20% before establishing a bullish crossover. This leaves the door open to a possible pullback by the Index before gaining bullish momentum. This means the Index, while in a long-term uptrend, could sell off over the coming months but hold above the July low of 96.37. With the US 10-year T-note (ZNU25), I'm going to continue to call the long-term trend sideways. If the US Fed is forced to raise interest rates to fight inflation tied to trade wars and tariffs, longer-term US Treasury instruments could come under increased pressure. As of the end of July, the 10-year futures market continues to consolidate within the April 2025 range. As for long-term positions, it's possible longs were established near the November 2023 close of 109-150 based on a bullish 2-month reversal pattern[ii]. The Teucrium Corn Fund (CORN) is also in a long-term sideways trend. CORN closed July at $17.26, down $0.43 for the month after posting a low of $17.11. This held the August 2024 mark of $17.02. Long-term investors might've bought CORN near the August 2024 settlement of $17.70. Is there a fundamental reason to be long CORN? As July came to an end, the deferred the May26-Jul26 futures spread covered a bullish 30% calculated full commercial carry[iii] indicating the commercial side is not as optimistic about supplies in relation to demand next spring. For comparison, the end of June saw this same spread covering 32% while the 2025 edition of the spread covered 36% at the end of July 2024. The Teucrium Soybean Fund (SOYB) is in a major sideways trend, highlighted by converging trendlines. July saw SOYB close at $21.21, down $0.57 for the month. support remains at the previous 4-month low of $20.59 (April 2025) with resistance at the previous 4-month high of $22.65 (June 2025). It's possible Investors bought near the December settlement of $21.48 based on the completion of a bullish spike reversal pattern[iv] as 2024 came to an end. From a fundamental point of view, this same group of investors are likely not as enthusiastic as they are in corn. The Nov25-Jul26 forward curve closed July at a carry of 60.5 cents and covered a neutral 56% calculated full commercial carry as compared to the end of June 44% and the Nov24-Jul25 spread's 56.5 cents carry and 49% at the end of July 2024. The bottom line is supply and demand is less bullish than it was a year ago at this time. The Teucrium Wheat Fund (WEAT) remains in a major downtrend as it posted a new low of $4.29 in late July before closing at $4.35, down $0.09 for the month. This was also a new all-time low monthly close. Fundamentally the Sept25-May26 forward curve closed July at a carry of 49.25 cents and covered 56% calculated full commercial carry. The June close showed a carry of 51.5 cents and 58% with the Sept24-May25 spread finishing July 2024 at a carry of 58.0 cents and 64%. Investors are likely on the sidelines, though some may have gone long on the idea of 'How Much Lower Can It Go'? To them I will show the monthly close-only chart for Beyond Meat (BYND). [i] The Index traded outside the June range before closing higher for the month. This is one of the more reliable technical reversal patterns I look for on any time frame (short-term daily, intermediate-term weekly, long-term monthly). [ii] Month 1 sees the market close near its monthly low before closing near its monthly high at the end of Month 2. [iii] Total cost of storage and interest to hold cash bushels in commercial storage. [iv] The market moved to a new low for the previous downtrend before closing higher for the month. On the date of publication, Darin Newsom did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
